Global Virtual Congress

Immunõ 2026: Global Virtual Congress on Immuno Oncology

Table of contents

Overview

Event Series

O Series

Date / Time

Sep 24, 2026 – Sep 30, 2026

Save to

Google Calendar Outlook Calendar

Watch

DAY 4

Immunõ 2026: Global Virtual Congress on Immuno Oncology September 27 https://t.co/2uwUAAPS5a

— OncoDaily (@oncodaily) September 27, 2026

DAY 3: https://x.com/i/broadcasts/1NGaroXZplQJj
DAY 2: https://x.com/i/broadcasts/1jGXgBnMWkvKZ
DAY 1: https://x.com/i/broadcasts/1YGNrbqDeQXGw

Presented by OncoDaily in partnership with the Parker Institute for Cancer Immunotherapy

The Immunõ 2026 Global Virtual Congress on Immuno-Oncology is an international scientific event bringing together leading experts in cancer immunology, immunotherapy, translational research, clinical oncology, and patient advocacy.

Presented by OncoDaily in partnership with the Parker Institute for Cancer Immunotherapy, the congress will create a global platform for exploring the scientific discoveries, clinical advances, and multidisciplinary collaborations shaping the future of cancer immunotherapy.

As the Parker Institute for Cancer Immunotherapy marks its 10th anniversary, Immunõ 2026 will also highlight a decade of progress in collaborative cancer immunotherapy research while looking ahead to the next generation of immune-based cancer treatments.

Speakers

Images	Name
	Karen E. Knudsen — San Francisco, CA, USA Chief Executive Officer and Board Member, Parker Institute for Cancer Immunotherapy (PICI) Professor Emerita, Thomas Jefferson University and Sidney Kimmel Cancer Center
	Justin Stebbing — United Kingdom Medical Oncologist and Translational Cancer Research Leader Professor of Biomedical Sciences, Anglia Ruskin University Editor-in-Chief, Oncogene
	Hesham Elghazaly — Egypt Professor of Clinical Oncology, Ain Shams University President, Egyptian Cancer Society
	Garo H. Armen — Lexington, MA, USA Co-Founder, Chairman and Chief Executive Officer, Agenus Biotechnology Executive and Cancer Immunotherapy Pioneer
	Alicia Zhou — New York, NY, USA Chief Executive Officer, Cancer Research Institute (CRI) Cancer Scientist and Immunotherapy Research Executive
	Ryan Schoenfeld — New York, NY, USA Chief Executive Officer, The Mark Foundation for Cancer Research
	Judith Agudo — Boston, MA, USA Associate Professor, Dana-Farber Cancer Institute and Harvard Medical School Principal Investigator, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute
	Kristen Dahlgren — Central Vermont / San Francisco, CA, USA Chief External Affairs Officer, Parker Institute for Cancer Immunotherapy Founder, Cancer Vaccine Coalition
	Taha Merghoub — New York, NY, USA Deputy Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine Margaret and Herman Sokol Professor of Oncology Research; Professor of Pharmacology and Immunology Research in Medicine, Weill Cornell Medicine
	Philip M. Arlen — Bethesda, MD, USA President and Chief Executive Officer, Precision Biologics Clinical Staff, National Cancer Institute, NIH
	Howard L. Kaufman — Boston, MA, USA President and Chief Executive Officer, Ankyra Therapeutics Associate Professor of Surgery, Harvard Medical School
	Moran Amit — Houston, TX, USA Assistant Professor, Department of Head and Neck Surgery, MD Anderson Cancer Center Cancer Neuroscientist and Head and Neck Cancer Research Leader
	Stephen Gottschalk — Memphis, TN, USA Chair, Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital Co-Director, Center of Excellence for Pediatric Immuno-Oncology
	Alejandro Madrigal — Monterrey, Mexico / London, United Kingdom FEMSA Distinguished Professor in Hematology and Cellular Therapy, Tecnológico de Monterrey Professor of Haematology, UCL Cancer Institute
	Lisa H. Butterfield — San Francisco, CA, USA Cancer Immunotherapy Scientist and Biomarker Research Leader Former Vice President of Research and Development, Parker Institute for Cancer Immunotherapy
	Ghassan K. Abou-Alfa — New York, NY, USA Attending Physician, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Global Leader in Hepatobiliary and Gastrointestinal Oncology
	Guillem Argilés — New York, NY, USA Medical Oncologist and Colorectal Cancer Research Leader Senior Researcher, Luis Diaz Laboratory, Memorial Sloan Kettering Cancer Center Expert in Colorectal Cancer, Immunotherapy and Precision Oncology
	Joshua Brody — New York, NY, USA Director, Lymphoma Immunotherapy Program, Mount Sinai Tisch Cancer Center Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai
	Ira Mellman — San Francisco, CA, USA President of Research, Parker Institute for Cancer Immunotherapy Cancer Immunology and Cell Biology Pioneer; Former Vice President of Cancer Immunology, Genentech
	David A. Barbie — Boston, MA, USA Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School; Jane Rodgers Chair at Dana-Farber; Associate Director, Belfer Center for Applied Cancer Science
	James C. Yang — Bethesda, MD, USA Senior Investigator, Surgery Branch, National Cancer Institute, National Institutes of Health Surgical oncologist and cancer immunotherapy researcher focused on adoptive T-cell therapy, tumor-infiltrating lymphocytes, engineered T-cell receptors, and solid tumors.
	Miriam Merad — New York, NY, USA Dean for Translational Research and Therapeutic Innovation, Icahn School of Medicine at Mount Sinai Chair, Department of Immunology and Immunotherapy, Mount Sinai
	Jing Wen — Los Angeles, CA, USA Associate Adjunct Professor, David Geffen School of Medicine at UCLA Researcher in Immunotherapy, Gene Therapy and Nanomedicine
	Carl H. June — Philadelphia, PA, USA Richard W. Vague Professor in Immunotherapy, University of Pennsylvania Director, Center for Cellular Immunotherapies, University of Pennsylvania Director, Parker Institute for Cancer Immunotherapy at Penn
	Omar Alhalabi — Houston, TX, USA Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center
	Paulina Velasquez — Memphis, TN, USA Associate Member, Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital Principal Investigator, Velasquez Lab
	Prasad S. Adusumilli — New York, NY, USA Professor and Deputy Chief, Thoracic Service, Memorial Sloan Kettering Cancer Center Vice Chair for Translational Research, Department of Surgery, MSK
	Sandro Matosevic — West Lafayette, IN, USA Associate Professor, Purdue University
	Thomas G. Martin — San Francisco, CA, USA Clinical Professor of Medicine, University of California, San Francisco Clinical Research Director of Hematologic Malignancies, UCSF
	Thomas U. Marron — New York, NY, USA Associate Director for Translational Research, Mount Sinai Tisch Cancer Center Director, Early Phase Trials Unit, Mount Sinai
	Stephen C. Frederico — Pittsburgh, PA, USA Fourth-Year Medical Student, University of Pittsburgh School of Medicine Translational Neuro-Oncology Researcher
	Mark J. Ratain — Chicago, IL, USA Leon O. Jacobson Professor of Medicine, The University of Chicago Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, University of Chicago Comprehensive Cancer Center; Chief Hospital Pharmacologist, University of Chicago Medical Center
	Eduardo Cazap — Argentina Founder and First President, Latin American and Caribbean Society of Medical Oncology (SLACOM)
	Gilberto D. Lopes — Miami, FL, USA Chief, Division of Medical Oncology, University of Miami Miller School of Medicine Associate Director for Global Oncology, Sylvester Comprehensive Cancer Cente
	F. Stephen Hodi — Boston, MA, USA Director, Melanoma Center, Dana-Farber Cancer Institute Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute
	Theodore (Theo) Roth — Stanford, CA, USA Assistant Professor of Pathology, Stanford University Senior Fellow, Parker Institute for Cancer Immunotherapy (PICI)
	Scott C. Howard — Memphis, TN, USA Founder and Chief Executive Officer, Resonance Deputy Director, Yeolyan Hematology Oncology Center; International Development Officer, Hospital Sant Joan de Déu Barcelona
	Larry Norton — New York, NY, USA Senior Vice President, Office of the Hospital President, Memorial Sloan Kettering Cancer Center Medical Director, Evelyn H. Lauder Breast Center Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center
	Mehdi Benzaoui — New York, USA Postdoctoral Associate in Pharmacology, Weill Cornell Medicine Postdoctoral Fellow, Merghoub–Wolchok Laboratory 2025 Parker Scholar, Parker Institute for Cancer Immunotherapy
	Maxime Meylan — Boston, USA Instructor in Immunology, Dana-Farber Cancer Institute Instructor in Immunology, Harvard Medical School Parker Bridge Fellow, Parker Institute for Cancer Immunotherapy
	Hyuncheol Jung — San Francisco, CA, USA Postdoctoral Scholar, UCSF–Gladstone Institute of Genomic Immunology Postdoctoral Fellow, Marson and Carnevale Laboratories 2025 Parker Scholar, Parker Institute for Cancer Immunotherapy
	Angelica Loskog — Uppsala, Sweden Chief Executive Officer and Chief Scientific Officer, Lokon Pharma Adjunct Professor, Department of Immunology, Genetics and Pathology, Uppsala University
	Annalice Gandini — Italy Medical Oncologist, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa Researcher, Centre de Recherche des Cordeliers, Paris
	Catherine Sautès-Fridman — France Professor Emeritus, Université Paris Cité Co-Group Leader, Immunotherapy and Cancer Group, Centre de Recherche des Cordeliers
	Valentin (Vali) Barsan — South San Francisco, CA, USA Chief Executive Officer, Kamau Therapeutics Physician-Scientist in Cancer Immunotherapy and Cell & Gene Therapy
	Stephanie Kauffman — New York, NY, USA Chief Executive Officer, Melanoma Research Alliance Cancer Research, Philanthropy, and Strategic Partnerships Leader
	Ari Rosenberg — Chicago, IL, USA Associate Professor of Medicine, University of Chicago Medical Oncologist specializing in head and neck cancer, thyroid cancer, and immunotherapy.
	Verna Vanderpuye — Ghana Senior Consultant Clinical Oncologist and Deputy Director, National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital Adjunct Professor of Oncology, Queen’s University
	Panagiotis J. Vlachostergios — Larissa, Greece Medical Oncologist, Department of Medical Oncology, IASO Thessalias General Hospital Assistant Professor of Clinical Medicine (Courtesy), Weill Cornell Medical College
	Antoine Italiano — France Therapeutic Innovation Department, Sarcoma Group Gustave Roussy
	Amol Akhade — India Consultant, Medical Oncology, Fortis Hospital Mulund, Mumbai Medical Oncologist specializing in Precision Oncology and Hemato-Oncology
	Ruzanna Papyan — Armenia Chief, Pediatric Oncology Department, Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center Assistant Professor, Yerevan State Medical University
	Crystal Mackall — Stanford, CA, USA Founding Director, Stanford Center for Cancer Cell Therapy Director, Parker Institute for Cancer Immunotherapy at Stanford; Professor of Pediatrics and Medicine, Stanford University
	Pashtoon M. Kasi — Irvine, CA, USA Medical Director of GI Medical Oncology, City of Hope Orange County Rad Family Chair in Gastrointestinal Oncology; Associate Clinical Professor, City of Hope
	Alisa Dietl, MD, PhD — San Francisco, CA, USA Postdoctoral Fellow, Gladstone-UCSF Institute of Genomic ImmunologyParker Scholar, Parker Institute for Cancer Immunotherapy CIRM Clinical Scholar, California Institute for Regenerative Medicine
	André Ilbawi — Switzerland Cancer Control Officer, World Health Organization (WHO) Cancer Programme Technical Leader, WHO Headquarters, Geneva
	Oluwatayo (Tayo) F. Ikotun — Los Angeles, CA, USA Assistant Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA Principal Investigator, Crump Institute for Molecular Imaging; Leader, Laboratory for Image-Guided Immunotherapy
	Aparna R. Parikh — Boston, MA, USA Program Director, GI Oncology, Mass General Brigham Cancer Institute Associate Professor of Medicine, Harvard Medical School; Director, Global Cancer Care Program, Massachusetts General Hospital
	Preeti Singh — Princeton, NJ, USA Medical Affairs and Clinical Development, Legend Biotech Physician executive focused on cell therapy, immuno-oncology, and oncology drug development
	Khaoula Mazouzi — Houston, TX, USA Fellow, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Oncologist focused on leukemia, CAR T-cell therapy, and hematopoietic stem cell transplantation
	Sandra P. D’Angelo — New York, NY, USA Medical Oncologist and Attending Physician, Memorial Sloan Kettering Cancer Center Sarcoma and Cellular Immunotherapy Specialist
	Martha Raymond — Boston, MA / New York, NY, USA Founder and CEO, GI Cancers Alliance; Founder and CEO, The Raymond Foundation GI Cancer Advocacy and Patient-Reported Outcomes Leader

Scientific Focus

The Immunõ 2026 scientific program will focus on the most important scientific, clinical, and global challenges currently shaping immuno-oncology.

The program is being developed around major themes including checkpoint immunotherapy, the tumor microenvironment, cellular therapies, personalized cancer vaccines, biomarker-driven patient selection, toxicity management, disease-specific clinical immunotherapy, global access, and health equity.

Invited faculty will be asked to indicate their preferred scientific sections and presentation interests to help align speakers with the final agenda.

Session chairs and scientific leaders will be identified as the program continues to develop.

Who Should Attend?

Immunõ 2026 is designed for professionals and stakeholders involved in cancer research, diagnosis, treatment, supportive care, and patient advocacy, including:

Medical oncologists
Hematologists and hemato-oncologists
Immunologists
Translational researchers
Laboratory scientists
Clinical investigators
Pathologists and molecular diagnosticians
Surgical oncologists
Radiation oncologists
Oncology nurses
Advanced practice providers
Oncology pharmacists
Biotechnology and pharmaceutical researchers
Clinical research professionals
Medical students, residents, and fellows
Patient advocates, patients, and caregivers

Why Attend?

Learn From Global Experts

Hear perspectives from leading clinicians, scientists, researchers, and multidisciplinary specialists working across cancer immunology and immunotherapy.

Explore Emerging Science

Review developments in biomarkers, resistance, cellular therapies, combination treatments, and next-generation immune-based approaches.

Connect Research With Practice

Understand how scientific discoveries and clinical evidence can inform treatment decisions and improve patient care.

Examine Unmet Challenges

Discuss treatment resistance, immune-related toxicities, patient selection, access barriers, and disparities in immunotherapy delivery.

Join an International Scientific Exchange

Connect with participants representing different specialties, institutions, countries, and healthcare systems.

Speakers

Images	Name
	Karen E. Knudsen — San Francisco, CA, USA Chief Executive Officer and Board Member, Parker Institute for Cancer Immunotherapy (PICI) Professor Emerita, Thomas Jefferson University and Sidney Kimmel Cancer Center
	Justin Stebbing — United Kingdom Medical Oncologist and Translational Cancer Research Leader Professor of Biomedical Sciences, Anglia Ruskin University Editor-in-Chief, Oncogene
	Hesham Elghazaly — Egypt Professor of Clinical Oncology, Ain Shams University President, Egyptian Cancer Society
	Garo H. Armen — Lexington, MA, USA Co-Founder, Chairman and Chief Executive Officer, Agenus Biotechnology Executive and Cancer Immunotherapy Pioneer
	Alicia Zhou — New York, NY, USA Chief Executive Officer, Cancer Research Institute (CRI) Cancer Scientist and Immunotherapy Research Executive
	Ryan Schoenfeld — New York, NY, USA Chief Executive Officer, The Mark Foundation for Cancer Research
	Judith Agudo — Boston, MA, USA Associate Professor, Dana-Farber Cancer Institute and Harvard Medical School Principal Investigator, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute
	Kristen Dahlgren — Central Vermont / San Francisco, CA, USA Chief External Affairs Officer, Parker Institute for Cancer Immunotherapy Founder, Cancer Vaccine Coalition
	Taha Merghoub — New York, NY, USA Deputy Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine Margaret and Herman Sokol Professor of Oncology Research; Professor of Pharmacology and Immunology Research in Medicine, Weill Cornell Medicine
	Philip M. Arlen — Bethesda, MD, USA President and Chief Executive Officer, Precision Biologics Clinical Staff, National Cancer Institute, NIH
	Howard L. Kaufman — Boston, MA, USA President and Chief Executive Officer, Ankyra Therapeutics Associate Professor of Surgery, Harvard Medical School
	Moran Amit — Houston, TX, USA Assistant Professor, Department of Head and Neck Surgery, MD Anderson Cancer Center Cancer Neuroscientist and Head and Neck Cancer Research Leader
	Stephen Gottschalk — Memphis, TN, USA Chair, Department of Bone Marrow Transplantation & Cellular Therapy, St. Jude Children’s Research Hospital Co-Director, Center of Excellence for Pediatric Immuno-Oncology
	Alejandro Madrigal — Monterrey, Mexico / London, United Kingdom FEMSA Distinguished Professor in Hematology and Cellular Therapy, Tecnológico de Monterrey Professor of Haematology, UCL Cancer Institute
	Lisa H. Butterfield — San Francisco, CA, USA Cancer Immunotherapy Scientist and Biomarker Research Leader Former Vice President of Research and Development, Parker Institute for Cancer Immunotherapy
	Ghassan K. Abou-Alfa — New York, NY, USA Attending Physician, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Global Leader in Hepatobiliary and Gastrointestinal Oncology
	Guillem Argilés — New York, NY, USA Medical Oncologist and Colorectal Cancer Research Leader Senior Researcher, Luis Diaz Laboratory, Memorial Sloan Kettering Cancer Center Expert in Colorectal Cancer, Immunotherapy and Precision Oncology
	Joshua Brody — New York, NY, USA Director, Lymphoma Immunotherapy Program, Mount Sinai Tisch Cancer Center Associate Professor of Medicine, Icahn School of Medicine at Mount Sinai
	Ira Mellman — San Francisco, CA, USA President of Research, Parker Institute for Cancer Immunotherapy Cancer Immunology and Cell Biology Pioneer; Former Vice President of Cancer Immunology, Genentech
	David A. Barbie — Boston, MA, USA Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School; Jane Rodgers Chair at Dana-Farber; Associate Director, Belfer Center for Applied Cancer Science
	James C. Yang — Bethesda, MD, USA Senior Investigator, Surgery Branch, National Cancer Institute, National Institutes of Health Surgical oncologist and cancer immunotherapy researcher focused on adoptive T-cell therapy, tumor-infiltrating lymphocytes, engineered T-cell receptors, and solid tumors.
	Miriam Merad — New York, NY, USA Dean for Translational Research and Therapeutic Innovation, Icahn School of Medicine at Mount Sinai Chair, Department of Immunology and Immunotherapy, Mount Sinai
	Jing Wen — Los Angeles, CA, USA Associate Adjunct Professor, David Geffen School of Medicine at UCLA Researcher in Immunotherapy, Gene Therapy and Nanomedicine
	Carl H. June — Philadelphia, PA, USA Richard W. Vague Professor in Immunotherapy, University of Pennsylvania Director, Center for Cellular Immunotherapies, University of Pennsylvania Director, Parker Institute for Cancer Immunotherapy at Penn
	Omar Alhalabi — Houston, TX, USA Assistant Professor, Genitourinary Medical Oncology, MD Anderson Cancer Center
	Paulina Velasquez — Memphis, TN, USA Associate Member, Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital Principal Investigator, Velasquez Lab
	Prasad S. Adusumilli — New York, NY, USA Professor and Deputy Chief, Thoracic Service, Memorial Sloan Kettering Cancer Center Vice Chair for Translational Research, Department of Surgery, MSK
	Sandro Matosevic — West Lafayette, IN, USA Associate Professor, Purdue University
	Thomas G. Martin — San Francisco, CA, USA Clinical Professor of Medicine, University of California, San Francisco Clinical Research Director of Hematologic Malignancies, UCSF
	Thomas U. Marron — New York, NY, USA Associate Director for Translational Research, Mount Sinai Tisch Cancer Center Director, Early Phase Trials Unit, Mount Sinai
	Stephen C. Frederico — Pittsburgh, PA, USA Fourth-Year Medical Student, University of Pittsburgh School of Medicine Translational Neuro-Oncology Researcher
	Mark J. Ratain — Chicago, IL, USA Leon O. Jacobson Professor of Medicine, The University of Chicago Director, Center for Personalized Therapeutics; Associate Director for Clinical Sciences, University of Chicago Comprehensive Cancer Center; Chief Hospital Pharmacologist, University of Chicago Medical Center
	Eduardo Cazap — Argentina Founder and First President, Latin American and Caribbean Society of Medical Oncology (SLACOM)
	Gilberto D. Lopes — Miami, FL, USA Chief, Division of Medical Oncology, University of Miami Miller School of Medicine Associate Director for Global Oncology, Sylvester Comprehensive Cancer Cente
	F. Stephen Hodi — Boston, MA, USA Director, Melanoma Center, Dana-Farber Cancer Institute Director, Center for Immuno-Oncology, Dana-Farber Cancer Institute
	Theodore (Theo) Roth — Stanford, CA, USA Assistant Professor of Pathology, Stanford University Senior Fellow, Parker Institute for Cancer Immunotherapy (PICI)
	Scott C. Howard — Memphis, TN, USA Founder and Chief Executive Officer, Resonance Deputy Director, Yeolyan Hematology Oncology Center; International Development Officer, Hospital Sant Joan de Déu Barcelona
	Larry Norton — New York, NY, USA Senior Vice President, Office of the Hospital President, Memorial Sloan Kettering Cancer Center Medical Director, Evelyn H. Lauder Breast Center Norna S. Sarofim Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center
	Mehdi Benzaoui — New York, USA Postdoctoral Associate in Pharmacology, Weill Cornell Medicine Postdoctoral Fellow, Merghoub–Wolchok Laboratory 2025 Parker Scholar, Parker Institute for Cancer Immunotherapy
	Maxime Meylan — Boston, USA Instructor in Immunology, Dana-Farber Cancer Institute Instructor in Immunology, Harvard Medical School Parker Bridge Fellow, Parker Institute for Cancer Immunotherapy
	Hyuncheol Jung — San Francisco, CA, USA Postdoctoral Scholar, UCSF–Gladstone Institute of Genomic Immunology Postdoctoral Fellow, Marson and Carnevale Laboratories 2025 Parker Scholar, Parker Institute for Cancer Immunotherapy
	Angelica Loskog — Uppsala, Sweden Chief Executive Officer and Chief Scientific Officer, Lokon Pharma Adjunct Professor, Department of Immunology, Genetics and Pathology, Uppsala University
	Annalice Gandini — Italy Medical Oncologist, Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa Researcher, Centre de Recherche des Cordeliers, Paris
	Catherine Sautès-Fridman — France Professor Emeritus, Université Paris Cité Co-Group Leader, Immunotherapy and Cancer Group, Centre de Recherche des Cordeliers
	Valentin (Vali) Barsan — South San Francisco, CA, USA Chief Executive Officer, Kamau Therapeutics Physician-Scientist in Cancer Immunotherapy and Cell & Gene Therapy
	Stephanie Kauffman — New York, NY, USA Chief Executive Officer, Melanoma Research Alliance Cancer Research, Philanthropy, and Strategic Partnerships Leader
	Ari Rosenberg — Chicago, IL, USA Associate Professor of Medicine, University of Chicago Medical Oncologist specializing in head and neck cancer, thyroid cancer, and immunotherapy.
	Verna Vanderpuye — Ghana Senior Consultant Clinical Oncologist and Deputy Director, National Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital Adjunct Professor of Oncology, Queen’s University
	Panagiotis J. Vlachostergios — Larissa, Greece Medical Oncologist, Department of Medical Oncology, IASO Thessalias General Hospital Assistant Professor of Clinical Medicine (Courtesy), Weill Cornell Medical College
	Antoine Italiano — France Therapeutic Innovation Department, Sarcoma Group Gustave Roussy
	Amol Akhade — India Consultant, Medical Oncology, Fortis Hospital Mulund, Mumbai Medical Oncologist specializing in Precision Oncology and Hemato-Oncology
	Ruzanna Papyan — Armenia Chief, Pediatric Oncology Department, Pediatric Cancer and Blood Disorders Center of Armenia, Yeolyan Hematology and Oncology Center Assistant Professor, Yerevan State Medical University
	Crystal Mackall — Stanford, CA, USA Founding Director, Stanford Center for Cancer Cell Therapy Director, Parker Institute for Cancer Immunotherapy at Stanford; Professor of Pediatrics and Medicine, Stanford University
	Pashtoon M. Kasi — Irvine, CA, USA Medical Director of GI Medical Oncology, City of Hope Orange County Rad Family Chair in Gastrointestinal Oncology; Associate Clinical Professor, City of Hope
	Alisa Dietl, MD, PhD — San Francisco, CA, USA Postdoctoral Fellow, Gladstone-UCSF Institute of Genomic ImmunologyParker Scholar, Parker Institute for Cancer Immunotherapy CIRM Clinical Scholar, California Institute for Regenerative Medicine
	André Ilbawi — Switzerland Cancer Control Officer, World Health Organization (WHO) Cancer Programme Technical Leader, WHO Headquarters, Geneva
	Oluwatayo (Tayo) F. Ikotun — Los Angeles, CA, USA Assistant Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA Principal Investigator, Crump Institute for Molecular Imaging; Leader, Laboratory for Image-Guided Immunotherapy
	Aparna R. Parikh — Boston, MA, USA Program Director, GI Oncology, Mass General Brigham Cancer Institute Associate Professor of Medicine, Harvard Medical School; Director, Global Cancer Care Program, Massachusetts General Hospital
	Preeti Singh — Princeton, NJ, USA Medical Affairs and Clinical Development, Legend Biotech Physician executive focused on cell therapy, immuno-oncology, and oncology drug development
	Khaoula Mazouzi — Houston, TX, USA Fellow, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center Oncologist focused on leukemia, CAR T-cell therapy, and hematopoietic stem cell transplantation
	Sandra P. D’Angelo — New York, NY, USA Medical Oncologist and Attending Physician, Memorial Sloan Kettering Cancer Center Sarcoma and Cellular Immunotherapy Specialist
	Martha Raymond — Boston, MA / New York, NY, USA Founder and CEO, GI Cancers Alliance; Founder and CEO, The Raymond Foundation GI Cancer Advocacy and Patient-Reported Outcomes Leader

Scientific Focus

The Immunõ 2026 scientific program will focus on the most important scientific, clinical, and global challenges currently shaping immuno-oncology.

Invited faculty will be asked to indicate their preferred scientific sections and presentation interests to help align speakers with the final agenda.

Session chairs and scientific leaders will be identified as the program continues to develop.

Who Should Attend?

Immunõ 2026 is designed for professionals and stakeholders involved in cancer research, diagnosis, treatment, supportive care, and patient advocacy, including:

Why Attend?

Learn From Global Experts

Hear perspectives from leading clinicians, scientists, researchers, and multidisciplinary specialists working across cancer immunology and immunotherapy.

Explore Emerging Science

Review developments in biomarkers, resistance, cellular therapies, combination treatments, and next-generation immune-based approaches.

Connect Research With Practice

Understand how scientific discoveries and clinical evidence can inform treatment decisions and improve patient care.

Examine Unmet Challenges

Discuss treatment resistance, immune-related toxicities, patient selection, access barriers, and disparities in immunotherapy delivery.

Join an International Scientific Exchange

Connect with participants representing different specialties, institutions, countries, and healthcare systems.

Agenda

IMMUNÕ 2026

Scientific Program

24–30 September 2026 · Provisional program

All times are US Eastern (EDT, UTC−4). Times and topics are subject to confirmation.

Day 1 · Thursday, 24 September 2026

Anniversary leadership and the next decade

Time (US Eastern) EDT · UTC−4	Session details
11:00 – 11:15 AM	Karen E. Knudsen — Opening the PICI tenth anniversary congress
11:15 – 11:40 AM	Ira Mellman — The Cancer-Immunity Cycle and the Next Scientific Frontiers
11:40 AM – 12:10 PM	Dr. Vlachostergios — The Evolving Role of Immunotherapy in Genitourinary Cancers
12:10 – 12:30 PM	Carl H. June — Evolution of CAR-T and the road to solid tumours
12:30 – 1:05 PM	Break
1:05 – 1:25 PM	Sarah Weiss — Melanoma after progression on checkpoint blockade
1:25 – 1:50 PM	Guillem Argilés — GI cancers after progression on checkpoint blockade / Immunotherapy Era in GI Cancers
1:50 – 2:05 PM	Taha Merghoub — Reading and Rewiring the Tumour Microenvironment: Neutrophils and Metabolic Targeting to Overcome TME Resistance
2:05 – 2:20 PM	Closing session

Time (US Eastern)	Speaker and Contribution
Day 2 · Friday, 25 September 2026
Rewiring the Tumour Microenvironment All times are US Eastern Time (ET).
11:00–11:20 AM	David Barbie Reading and Rewiring the Tumour Microenvironment
11:20–11:45 AM	Judith Agudo Immune Evasion in Triple-Negative Breast Cancer
11:45 AM–12:15 PM	Catherine Sautès-Fridman Dysfunctional Tertiary Lymphoid Structures in Renal Cell Carcinoma
12:15–12:45 PM	Philip M. Arlen NEO-201 and Targeting Suppressive Immune Cells
12:45–1:20 PM	Shared Discussion From Immune Niches to Therapeutic Targeting With Taha Merghoub.
1:20–1:40 PM	Preeti Singh From Immuno-Oncology News to Competitive Advantage: The Strategic Signals Shaping the Next Wave of Cancer Innovation

Time (US Eastern)	Speaker and Contribution
Day 3 · Saturday, 26 September 2026
Vaccines and Local Immune Activation All times are US Eastern Time (ET).
11:30–11:50 AM	Lisa H. Butterfield Antigen Selection and Immune Monitoring in Cancer Vaccines
11:50 AM–12:05 PM	Joshua Brody In Situ Vaccination
12:05–12:25 PM	Jing Wen Protein-Based Nanotechnologies for Cancer Immunotherapy
12:40–12:55 PM	Howard L. Kaufman Local Immunotherapy and Systemic Immune Responses
12:55–1:10 PM	Vaccine Discussion Chaired by Lisa H. Butterfield.
1:10–1:20 PM	Care for Cancer Reinvented Presented by Rebecca A. Miksad
1:20–1:45 PM	Moran Amit Immunoprevention and Local Immunotherapy in Precancer
1:45–2:05 PM	Kristen Dahlgren Patient Priorities in Cancer Vaccine Development With Marybeth Gilliam.

Time (US Eastern)	Speaker and Contribution
Day 4 · Sunday, 27 September 2026
Clinical Decisions and Translational Immunotherapy All times are US Eastern Time (ET).
10:40–11:00 AM	Ghassan Abou-Alfa Liver Cancer: TACE Plus Immunotherapy After EMERALD-3
11:00–11:25 AM	Hesham El-Ghazali Immunotherapy in Breast and Gynaecological Cancers
11:25–11:45 AM	Thomas U. Marron Neoadjuvant Immunotherapy in Liver Cancer
11:45 AM–12:05 PM	Annalice Gandini Neoadjuvant Immunotherapy in dMMR GI Tumours
12:05–12:20 PM	Stephanie Kauffman Melanoma Research and Patient Priorities
12:20–12:30 PM	Break
12:30–1:10 PM	Discussion: How I Treat the Patient With Molecular Residual Disease and No Visible Tumour With Aparna Parikh, Justin Stebbing and Antoine Italiano.
1:10–1:30 PM	Antoine Italiano Immunotherapy in Sarcoma
1:30–1:55 PM	Ari Rosenberg Response-Adaptive Immunotherapy in Head and Neck Cancers: Can Biomarkers Help Us Identify?
1:55–2:15 PM	F. Stephen Hodi Combination Strategies in Melanoma Immunotherapy
2:15–2:20 PM	Break
2:20–2:40 PM	Sandro Matosevic Immunometabolic Reprogramming of Natural Killer Cells for Solid Tumour Therapy

Time (US Eastern)	Speaker and Contribution
Day 5 · Monday, 28 September 2026
Cell Therapy and Paediatric Immunotherapy All times are US Eastern Time (ET).
10:05–10:40 AM	James Yang Adoptive T-Cell Therapy for Solid Malignancies: What’s Next?
10:40–11:00 AM	Prasad S. Adusumilli Regional Intrapleural Delivery of Mesothelin-Targeted CAR-T With Pembrolizumab: What the Phase I Proved, and What It Did Not
11:00–11:25 AM	Crystal Mackall Engineering Cellular Therapies for Cancer
11:25–11:35 AM	Theodore Roth Early-Career Research Presentation
11:35–11:45 AM	Alisia Dieli A Multiplexed Organoid-Based Tumour In Vivo Model as an Immunotherapy Testing and Discovery Platform Early-career research presentation
11:45–11:55 AM	Mehdi Benzaoui Early-Career Research Presentation
11:55 AM–12:05 PM	Hyuncheol Jung Virus-Like Particles Enable Targeted Gene Engineering and Pooled CRISPR Screening in Primary Human Myeloid Cells
12:05–12:15 PM	Maxime Meylan Early-Career Research Presentation
12:15–12:25 PM	Break
12:25–12:45 PM	Thomas Martin Cellular Immunotherapy in Multiple Myeloma
12:45–1:05 PM	Paulina Velasquez CAR T-Cell Therapy for AML and T-ALL
1:05–1:20 PM	Scott Howard How I Treat Relapsed/Refractory B-ALL in Children and Young Adults
1:20–1:35 PM	Ruzanna Papyan Anti-GD2 Immunotherapy in Neuroblastoma
1:35–1:50 PM	Paediatric Immunotherapy Discussion With Scott Howard, Ruzanna Papyan and Paulina Velasquez.
1:50–2:00 PM	Break
2:00–2:25 PM	Stephen Gottschalk Targeting Regnase-1 in B7-H3-CAR T Cells Reprograms the Tumour Microenvironment and Enhances Antitumour Efficacy Against Solid Tumours and Brain Tumours
2:25–2:45 PM	Stephen Frederico CAR-T Approaches for Paediatric Brain Tumours
2:45–3:00 PM	Sandra D’Angelo Afami-Cel in Synovial Sarcoma

Day 6 · Tuesday, 29 September 2026

Dose optimisation and better research decisions

Time (US Eastern) EDT · UTC−4	Session details
11:30 – 11:55 AM	Interventional pharmacoeconomics
11:55 AM – 12:25 PM	Practical questions in IO dose optimisation
12:25 – 12:30 PM	Rationale for low-dose immunotherapy trials
12:30 – 1:10 PM	Neurologic immune-related adverse events
1:10 – 1:20 PM	Molecular imaging of immune responses to cancer therapy
1:20 – 1:40 PM	CAR-T therapy beyond blood cancers
1:40 PM – TBC	Who Sets the Research Agenda? — panel discussion

Day 7 · Wednesday, 30 September 2026

Global access and immunotherapy education

Time (US Eastern) EDT · UTC−4	Session details
10:30 – 10:55 AM	Present and future challenges in developing cell therapy programmes and CAR-T treatments in Mexico and Latin America
10:55 – 11:15 AM	Delivering immunotherapy in resource-constrained settings
11:15 – 11:40 AM	Regional access discussion
11:40 AM – 1:30 PM	Break
1:30 – 1:45 PM	Immunotherapy education and evidence appraisal
1:45 – 2:00 PM	The Science That Comes Next: The Cancer-Immunity Cycle and the Next Scientific Frontiers

Immunõ 2026: Global Virtual Congress on Immuno Oncology

Overview

DAY 4

Presented by OncoDaily in partnership with the Parker Institute for Cancer Immunotherapy

Speakers

Karen E. Knudsen — San Francisco, CA, USA

Justin Stebbing — United Kingdom

Hesham Elghazaly — Egypt

Garo H. Armen — Lexington, MA, USA

Alicia Zhou — New York, NY, USA

Ryan Schoenfeld — New York, NY, USA

Judith Agudo — Boston, MA, USA

Kristen Dahlgren — Central Vermont / San Francisco, CA, USA

Taha Merghoub — New York, NY, USA

Philip M. Arlen — Bethesda, MD, USA

Howard L. Kaufman — Boston, MA, USA

Moran Amit — Houston, TX, USA

Stephen Gottschalk — Memphis, TN, USA

Alejandro Madrigal — Monterrey, Mexico / London, United Kingdom

Lisa H. Butterfield — San Francisco, CA, USA

Ghassan K. Abou-Alfa — New York, NY, USA

Guillem Argilés — New York, NY, USA

Joshua Brody — New York, NY, USA

Ira Mellman — San Francisco, CA, USA

David A. Barbie — Boston, MA, USA

James C. Yang — Bethesda, MD, USA

Miriam Merad — New York, NY, USA

Jing Wen — Los Angeles, CA, USA

Carl H. June — Philadelphia, PA, USA

Omar Alhalabi — Houston, TX, USA

Paulina Velasquez — Memphis, TN, USA

Prasad S. Adusumilli — New York, NY, USA

Sandro Matosevic — West Lafayette, IN, USA

Thomas G. Martin — San Francisco, CA, USA

Thomas U. Marron — New York, NY, USA

Stephen C. Frederico — Pittsburgh, PA, USA

Mark J. Ratain — Chicago, IL, USA

Eduardo Cazap — Argentina

Gilberto D. Lopes — Miami, FL, USA

F. Stephen Hodi — Boston, MA, USA

Theodore (Theo) Roth — Stanford, CA, USA

Scott C. Howard — Memphis, TN, USA

Larry Norton — New York, NY, USA

Mehdi Benzaoui — New York, USA

Maxime Meylan — Boston, USA

Hyuncheol Jung — San Francisco, CA, USA

Angelica Loskog — Uppsala, Sweden

Annalice Gandini — Italy

Catherine Sautès-Fridman — France

Valentin (Vali) Barsan — South San Francisco, CA, USA

Stephanie Kauffman — New York, NY, USA

Ari Rosenberg — Chicago, IL, USA

Verna Vanderpuye — Ghana

Panagiotis J. Vlachostergios — Larissa, Greece

Antoine Italiano — France

Amol Akhade — India

Ruzanna Papyan — Armenia

Crystal Mackall — Stanford, CA, USA

Pashtoon M. Kasi — Irvine, CA, USA

Alisa Dietl, MD, PhD — San Francisco, CA, USA

André Ilbawi — Switzerland

Oluwatayo (Tayo) F. Ikotun — Los Angeles, CA, USA

Aparna R. Parikh — Boston, MA, USA

Preeti Singh — Princeton, NJ, USA

Khaoula Mazouzi — Houston, TX, USA

Sandra P. D’Angelo — New York, NY, USA

Martha Raymond — Boston, MA / New York, NY, USA

Scientific Focus

Who Should Attend?

Why Attend?

About Immunõ 2026

About PICI

Speakers

Karen E. Knudsen — San Francisco, CA, USA

Justin Stebbing — United Kingdom

Hesham Elghazaly — Egypt

Garo H. Armen — Lexington, MA, USA

Alicia Zhou — New York, NY, USA

Ryan Schoenfeld — New York, NY, USA

Judith Agudo — Boston, MA, USA